These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7762722)

  • 1. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis.
    Jackson LA; Schuchat A; Gorsky RD; Wenger JD
    Am J Public Health; 1995 Jun; 85(6):843-5. PubMed ID: 7762722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis.
    Scott RD; Meltzer MI; Erickson LJ; De Wals P; Rosenstein NE
    Am J Prev Med; 2002 Aug; 23(2):98-105. PubMed ID: 12121797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
    Trotter CL; Edmunds WJ
    BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The costs associated with the public health management of a cluster of meningococcal infection in England.
    Letouze D; Yao G; Clarke SC
    Vaccine; 2014 Sep; 32(43):5549-51. PubMed ID: 25173479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases.
    Pediatrics; 2000 Dec; 106(6):1500-4. PubMed ID: 11099614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and opportunities for meningococcal vaccination in the developing world.
    Shaker R; Fayad D; Dbaibo G
    Hum Vaccin Immunother; 2018 May; 14(5):1084-1097. PubMed ID: 29393729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Bilukha OO; Rosenstein N;
    MMWR Recomm Rep; 2005 May; 54(RR-7):1-21. PubMed ID: 15917737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of meningococcal vaccination policies among colleges and universities - United States, 2017.
    Oliver SE; Patton ME; Hoban M; Leino V; Mbaeyi SA; Hariri S; MacNeil JR
    J Am Coll Health; 2021 Jul; 69(5):554-559. PubMed ID: 31710579
    [No Abstract]   [Full Text] [Related]  

  • 15. Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 2000 Jun; 49(RR-7):13-20. PubMed ID: 10902835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program.
    Bos JM; Rümke HC; Welte R; Postma MJ; Jager JC
    Vaccine; 2001 Oct; 20(1-2):202-7. PubMed ID: 11567765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningococcal vaccination for adolescents? An economic evaluation in Victoria.
    Skull SA; Butler JR
    J Paediatr Child Health; 2001 Oct; 37(5):S28-33. PubMed ID: 11885733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years.
    Rancourt C; Grégoire JP; Simons W; Dostie A
    Pharmacoeconomics; 2003; 21(6):429-42. PubMed ID: 12678569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.